Annual Cash & Cash Equivalents
$31.17 M
-$42.81 M-57.87%
December 31, 2023
Summary
- As of February 20, 2025, AVDL annual cash & cash equivalents is $31.17 million, with the most recent change of -$42.81 million (-57.87%) on December 31, 2023.
- During the last 3 years, AVDL annual cash & cash equivalents has fallen by -$40.55 million (-56.54%).
- AVDL annual cash & cash equivalents is now -71.57% below its all-time high of $109.62 million, reached on December 31, 2003.
Performance
AVDL Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$28.58 M
-$265.00 K-0.92%
September 30, 2024
Summary
- As of February 20, 2025, AVDL quarterly cash and cash equivalents is $28.58 million, with the most recent change of -$265.00 thousand (-0.92%) on September 30, 2024.
- Over the past year, AVDL quarterly cash and cash equivalents has dropped by -$2.58 million (-8.29%).
- AVDL quarterly cash and cash equivalents is now -73.93% below its all-time high of $109.62 million, reached on December 31, 2003.
Performance
AVDL Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
AVDL Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -57.9% | -8.3% |
| 3 y3 years | -56.5% | -42.8% |
| 5 y5 years | +234.2% | -42.8% |
AVDL Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -57.9% | at low | -65.7% | at low |
| 5 y | 5-year | -57.9% | +218.9% | -72.0% | +192.4% |
| alltime | all time | -71.6% | +2961.6% | -73.9% | +4967.7% |
Avadel Pharmaceuticals Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $28.58 M(-0.9%) |
| Jun 2024 | - | $28.85 M(-19.4%) |
| Mar 2024 | - | $35.79 M(+14.8%) |
| Dec 2023 | $31.17 M(-57.9%) | $31.17 M(-39.8%) |
| Sep 2023 | - | $51.81 M(+3.7%) |
| Jun 2023 | - | $49.98 M(-40.1%) |
| Mar 2023 | - | $83.39 M(+12.7%) |
| Dec 2022 | $73.98 M(+45.9%) | $73.98 M(+21.8%) |
| Sep 2022 | - | $60.72 M(+12.2%) |
| Jun 2022 | - | $54.13 M(-11.1%) |
| Mar 2022 | - | $60.87 M(+20.0%) |
| Dec 2021 | $50.71 M(-29.3%) | $50.71 M(-12.8%) |
| Sep 2021 | - | $58.17 M(-13.4%) |
| Jun 2021 | - | $67.14 M(+13.5%) |
| Mar 2021 | - | $59.17 M(-17.5%) |
| Dec 2020 | $71.72 M(+633.8%) | $71.72 M(-13.7%) |
| Sep 2020 | - | $83.11 M(-18.7%) |
| Jun 2020 | - | $102.17 M(+39.0%) |
| Mar 2020 | - | $73.51 M(+652.1%) |
| Dec 2019 | $9.77 M(+4.8%) | $9.77 M(-24.0%) |
| Sep 2019 | - | $12.87 M(-24.8%) |
| Jun 2019 | - | $17.11 M(+77.7%) |
| Mar 2019 | - | $9.63 M(+3.3%) |
| Dec 2018 | $9.32 M(-43.7%) | $9.32 M(-47.7%) |
| Sep 2018 | - | $17.84 M(+43.0%) |
| Jun 2018 | - | $12.48 M(-69.5%) |
| Mar 2018 | - | $40.91 M(+147.0%) |
| Dec 2017 | $16.56 M(-57.8%) | $16.56 M(-55.8%) |
| Sep 2017 | - | $37.45 M(-13.9%) |
| Jun 2017 | - | $43.51 M(+35.0%) |
| Mar 2017 | - | $32.24 M(-17.8%) |
| Dec 2016 | $39.22 M(-39.7%) | $39.22 M(+108.8%) |
| Sep 2016 | - | $18.78 M(-21.4%) |
| Jun 2016 | - | $23.90 M(-36.9%) |
| Mar 2016 | - | $37.87 M(-41.8%) |
| Dec 2015 | $65.06 M(+63.6%) | $65.06 M(+17.8%) |
| Jun 2015 | - | $55.24 M(+43.3%) |
| Mar 2015 | - | $38.53 M(-3.1%) |
| Dec 2014 | $39.76 M(+499.2%) | $39.76 M(+65.6%) |
| Sep 2014 | - | $24.01 M(-55.6%) |
| Jun 2014 | - | $54.10 M(-2.5%) |
| Mar 2014 | - | $55.51 M(+736.4%) |
| Dec 2013 | $6.64 M(+142.0%) | $6.64 M(-15.0%) |
| Sep 2013 | - | $7.81 M(-6.3%) |
| Jun 2013 | - | $8.34 M(-40.5%) |
| Mar 2013 | - | $14.01 M(+410.9%) |
| Dec 2012 | $2.74 M | $2.74 M(-42.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2012 | - | $4.75 M(+9.4%) |
| Mar 2012 | - | $4.35 M(+25.8%) |
| Dec 2011 | $3.46 M(-57.8%) | $3.46 M(-48.6%) |
| Sep 2011 | - | $6.73 M(-41.9%) |
| Jun 2011 | - | $11.58 M(+98.7%) |
| Mar 2011 | - | $5.83 M(-28.8%) |
| Dec 2010 | $8.18 M(-6.1%) | $8.18 M(+109.4%) |
| Sep 2010 | - | $3.91 M(+9.5%) |
| Jun 2010 | - | $3.57 M(+258.8%) |
| Mar 2010 | - | $995.00 K(-88.6%) |
| Dec 2009 | $8.72 M(-67.7%) | $8.72 M(+82.2%) |
| Sep 2009 | - | $4.78 M(-33.6%) |
| Jun 2009 | - | $7.21 M(-59.6%) |
| Mar 2009 | - | $17.85 M(-33.9%) |
| Dec 2008 | $27.02 M(+2.7%) | $27.02 M(-4.9%) |
| Sep 2008 | - | $28.41 M(+25.1%) |
| Jun 2008 | - | $22.70 M(-28.2%) |
| Mar 2008 | - | $31.61 M(+20.1%) |
| Dec 2007 | $26.31 M(-49.2%) | $26.31 M(-10.9%) |
| Sep 2007 | - | $29.54 M(-19.8%) |
| Jun 2007 | - | $36.82 M(-17.2%) |
| Mar 2007 | - | $44.44 M(-14.2%) |
| Dec 2006 | $51.83 M(+4991.1%) | $51.83 M(+9089.2%) |
| Sep 2006 | - | $564.00 K(-89.8%) |
| Jun 2006 | - | $5.54 M(+113.4%) |
| Mar 2006 | - | $2.60 M(+155.2%) |
| Dec 2005 | $1.02 M(-77.8%) | $1.02 M(-36.6%) |
| Sep 2005 | - | $1.61 M(+75.7%) |
| Jun 2005 | - | $914.00 K(-31.4%) |
| Mar 2005 | - | $1.33 M(-71.0%) |
| Dec 2004 | $4.59 M(-95.8%) | $4.59 M(-95.4%) |
| Sep 2004 | - | $100.85 M(0.0%) |
| Jun 2004 | - | $100.85 M(-4.3%) |
| Mar 2004 | - | $105.44 M(-3.8%) |
| Dec 2003 | $109.62 M(+654.6%) | $109.62 M(+396.5%) |
| Sep 2003 | - | $22.08 M(+89.5%) |
| Jun 2003 | - | $11.65 M(-18.6%) |
| Mar 2003 | - | $14.32 M(-1.4%) |
| Dec 2002 | $14.53 M(+173.6%) | $14.53 M(-0.7%) |
| Sep 2002 | - | $14.62 M(+175.4%) |
| Dec 2001 | $5.31 M(-47.6%) | $5.31 M(-47.6%) |
| Dec 2000 | $10.14 M(+94.6%) | $10.14 M(+94.6%) |
| Dec 1999 | $5.21 M(-28.4%) | $5.21 M(-28.4%) |
| Dec 1998 | $7.28 M(+91.5%) | $7.28 M(+21.3%) |
| Mar 1998 | - | $6.00 M(+57.9%) |
| Dec 1997 | $3.80 M(-75.5%) | $3.80 M(-75.5%) |
| Dec 1996 | $15.50 M | $15.50 M(+1191.7%) |
| Mar 1996 | - | $1.20 M |
FAQ
- What is Avadel Pharmaceuticals annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Avadel Pharmaceuticals?
- What is Avadel Pharmaceuticals annual cash & cash equivalents year-on-year change?
- What is Avadel Pharmaceuticals quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Avadel Pharmaceuticals?
- What is Avadel Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
What is Avadel Pharmaceuticals annual cash & cash equivalents?
The current annual cash & cash equivalents of AVDL is $31.17 M
What is the all time high annual cash & cash equivalents for Avadel Pharmaceuticals?
Avadel Pharmaceuticals all-time high annual cash & cash equivalents is $109.62 M
What is Avadel Pharmaceuticals annual cash & cash equivalents year-on-year change?
Over the past year, AVDL annual cash & cash equivalents has changed by -$42.81 M (-57.87%)
What is Avadel Pharmaceuticals quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of AVDL is $28.58 M
What is the all time high quarterly cash and cash equivalents for Avadel Pharmaceuticals?
Avadel Pharmaceuticals all-time high quarterly cash and cash equivalents is $109.62 M
What is Avadel Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
Over the past year, AVDL quarterly cash and cash equivalents has changed by -$2.58 M (-8.29%)